Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T12:55:47.633Z.
Calculation as of: 2026-10-06T12:55:47.633Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d0d16669f7a2c0e1646e6313a61118319ccaec2b3022f40527d46d929c834448
EARNINGS YIELD
N/A
Market Cap
$245.65M
Earnings Yield
N/A
TTM Avg
37.01%
3Y Avg
37.01%
5Y Avg
37.01%
Market Cap
$248.21M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$251.64M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioAge Labs Inc. (BIOA) | $239.45M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $239.89M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $236.56M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $244.25M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $245.65M | N/A | 37.01% | 37.01% | 37.01% |
| InflaRx N.V. (IFRX)vs › | $247.45M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $248.21M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $251.64M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $220.94M | N/A | 3.98% | 3.98% | 3.98% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
